| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef61d450301eef6e06ee65d1dd31bab7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2016-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c8c1d6afd026f632ce60392d656718d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16466c8dfdd027e71aae14c16c092330
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df58db1fd566502ccf9089c44b15b030
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b46737850af9d5ca4582f1ffdfaa96d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6453125874b9b3d3fca026cadf3b5111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_507329910a0fc82b7efae00295078c28 |
| publicationDate |
2016-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2016145191-A |
| titleOfInvention |
HAT acetylated promoter and use of the composition in promoting immunogenicity |
| abstract |
Increased presentation of major histocompatibility complex (MHC) class I surface molecules detected by cytotoxic T lymphocyte cells via increased antigen processing-related transporter (TAP) -1 expression Thus, the provision of methods and compositions for enhancing the immunogenicity of cells lacking TAP-1 expression. A pharmaceutical composition for use in treating a TAP-1-deficient cancer comprising a histone deacetylase inhibitor and a suitable adjuvant or carrier. The pharmaceutical composition further comprising a vaccine formulation. A pharmaceutical composition wherein the TAP-1-deficient cancer expresses a herpesvirus antigen or expresses a papillomavirus antigen. [Selection figure] None |
| priorityDate |
2007-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |